Long-Term Response and Survival in Extensive-Stage SCLC Receiving Atezolizumab Plus Chemotherapy in a Real-World Setting: IFCT-1905 CLINATEZO

Introduction: Extensive-stage SCLC (ES-SCLC) is a highly aggressive type of lung cancer with a high risk of early progression and limited survival. Standard of care for first-line treatment is platinum-etoposide chemotherapy plus anti–PD-L1 immune checkpoint inhibitors. Methods: Intergroupe Francoph...

Full description

Bibliographic Details

Published in:	JTO Clinical and Research Reports
Main Authors:	Lionel Falchero, MD, Karim Amrane, MD, Benoît Godbert, MD, Bénédicte Leterre, MD, Jeannick Madelaine, MD, Pierre Fournel, MD, PhD, Céline Mascaux, MD, PhD, Judith Raimbourg, MD, Sophie Schneider, MD, Aurélie Swalduz, MD, Rémi Veillon, MD, Alexandra Langlais, MSc, Pascale Missy, PhD, Franck Morin, MSc, Virginie Westeel, MD, PhD, Nicolas Girard, MD, PhD
Format:	Article
Language:	English
Published:	Elsevier 2026-04-01
Subjects:	Immunotherapy Long-term survival long-term response SCLC
Online Access:	http://www.sciencedirect.com/science/article/pii/S2666364326000159